Equipoise lost in pancreatic cancer: reimagining crossover for promising cancer therapies
Kruti B Vora, Susan E Bates · 2026
Read Equipoise lost in pancreatic cancer: reimagining crossover for promising cancer therapies by Kruti B Vora, Susan E Bates (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13628384.txt.
Description
Vora and Bates argue that pancreatic cancer trials face an ethics problem success itself created. A new drug, daraxonrasib, doubled median survival in pretreated patients, a leap in a disease where fifteen months is typical. Trials normally rest on equipoise, honest doubt about which arm is better, to justify random assignment. When early results look this strong, that doubt evaporates.
The authors trace why doubt once protected patients: a string of hopeful drugs failed in phase III despite strong beliefs. But crossover designs, letting control patients switch to the new drug, complicate survival math and delay answers. They call for rethinking crossover rules when a therapy's promise is exceptional, balancing fast access against proof that regulators and future patients can trust.
Catalog record
| CREATOR | Kruti B Vora, Susan E Bates |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 13 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |